Business
Integra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
PRINCETON, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth
About this update from Integra Lifesciences Holdings Corporation
[{"type":"text","content":"PRINCETON, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2022, consistent with its preliminary financial results announced on January 10, 2023 and January 25, 2023. Fourth Quarter 2022 Reported revenues were $398.0 million, representing a decrease of 1.8% on a reported basis and an increase of 2.9% on an organic basis compared to the fourth quarter 2021. GAAP earnings per diluted share were $0.63, compared to $0.53 in the fourth quarter 2021. Adjusted earnings per diluted share were $0.94, compared to $0.84 in the fourth quarter of 2021. Full-Year 2022 Reported revenues were 1,557.7 million representing an increase of 1.0% on a reported basis and an increase of 4.2% on an organic basis compared to full-year 2021. GAAP earnings per diluted share were $2.16, compared to $1.98 in 2021. Adjusted earnings per diluted share were $3.36, compared to $3.18 in 2021. Key Accomplishments in 2022 Advancing our portfolio: Extended the CUSA® Clarity portfolio with the launch of the laparoscopic and bone tipsLaunched Aurora® Evacuator plus coagulation in the U.S.U.S. launch of NeuraGen® 3DLaunched disposable instrument offeringInternational extension of Certas® Plus valve line and entered into distribution agreement for Neutus external ventricular drain (EVD) in China Completed the ACell portfolio integration and executed the commercial capacity build-out Further refined the portfolio by divesting non-core traditional wound care business (TWC) Completed the acquisition of Surgical Innovation Associates, which develops, markets and sells DuraSorb®, a resorbable mesh technology Completed strategic roadmap and M&A gameboard, including plans for international expansion Outsourced select global transactional back-office activities Closed a high-cost manufacturing facility in France Further strengthened executive leadership team with the appointment of the first chief digital officer and first executive vice president located outside the U.S. Developed sustainability baseline and strategy and published inaugural ESG report Named to Best Places to Work in NJ and Awarded Great Place to Work - Certified™ Organization in China “We made key advances in strengthening our strategic path. We met our organic growth and ex...